Tonix Pharmaceuticals presents data on real-world treatment of migraine

tonix Pharmaceuticals Holding presented data from a poster presentation at the 66th Annual Scientific Meeting of the American Headache Society, held June 13-16, 2024. In the poster presentation titled, “American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?,” a retrospective review of real-world data compares real world usage of non-oral migraine products with the most recent AHS consensus statement. The data reaffirms several past recommendations from the AHS and stresses the need for customizing treatment of migraine headaches to the needs of patients, as well as using the most appropriate route of administration for any given acute attack based on the clinical presentation. So far, real world data show that compliance with the guidelines and the consensus statement have yet to be achieved but has the potential to be increased. Specifically, the data show the use of non-oral drugs for treating an acute migraine attack was only 7% in 2012 and has decreased to below 4% in 2023, when the potential need for such drugs is anticipated to be a significant percentage of patients based on epidemiological data. Zembrace SymTouch is the only actively promoted brand of sumatriptan autoinjector in the U.S. It has a unique low dose and has demonstrated onset of migraine pain relief in as few as 10 minutes. Zembrace SymTouch also demonstrated migraine pain freedom for 46% of patients at 2 hours in a single-attack, double-blind study. Tosymra employs Intravail permeation enhancer technology and is pharmacokinetically equivalent to 4 mg subcutaneous sumatriptan. Tosymra delivers migraine pain relief in as little as 10 minutes with just one spray for some patients.